System and method for non-invasive monitoring of advanced glycation end-products (AGE)

A method performed by a medical device comprising processing circuitry and being configured to determine a concentration of an advanced glycation end-product (AGE), the method comprising:

• providing incident light, by a light emitter of the medical device, to tissue of a patient at one excitation wavelength;
• monitoring, by at least one photodetector of the medical device, an emission response to the incident light at a first emission wavelength and at a second emission wavelength;
• determining, by the processing circuitry, a concentration of the AGE based on a ratio of the emission response at the first emission wavelength to the emission response at the second emission wavelength, wherein the emission response at the first emission wavelength is associated with a maximum of the emission response and the emission response at the second emission wavelength is associated with a minimum of the emission response;
• comparing, by the processing circuitry, the determined concentration to a threshold;
• and
• generating, by the processing circuitry, an alert based on the comparison.

A system comprising:

• a medical device comprising:
• a light emitter configured to provide incident light to tissue of a patient at one excitation wavelength;
• at least one photodetector configured to monitor a first rate of autofluorescence decay of an emission response to the incident light at a first emission wavelength and a second rate of autofluorescence decay of the emission response at a second emission wavelength;
• and
• one or more processors configured to:
• determine a concentration of an advanced glycation end-product (AGE) based on a ratio of the first rate of autofluorescence decay of the emission response at the first emission wavelength to the second rate of autofluorescence decay of the emission response at the second emission wavelength.